Pegylated liposomal doxorubicin in stage IVB mycosis fungoides

British Journal of Dermatology

Volumn 153, Issue 1, 2005, Pages 183-185

  Di Lorenzo, Giuseppe ^a   Di Trolio, R ^a   Delfino, M ^a   De Placido, S ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Advanced disease; Chemotherapy; Mycosis fungoides; Pegylated liposomal doxorubicin

Indexed keywords

DOXORUBICIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MALE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG EVALUATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 22944452432     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06682.x     Document Type: Article

References (12)

1. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sézary syndrome. Blood 1996; 88:2385-409.
2. Kuzel TM, Guitar J, Rosen ST. Cutaneous T-cell lymphomas. In: Hematology. Basic Principles and Practice (Hoffman R, Benz EJ Jr, Shattil SJ et al., eds), 3rd edn. Philadelphia: Churchill Livingstone, 2000; 1372-87.
3. van Doorn R, van Haselen CW, van Voorst Vader PC et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000; 136:504-10.
4. Tirelli U, Errante D, van Glabbeke M et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16:27-34.
5. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1994; 54 (Suppl.):1-7.
6. Crawford J. Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat Rev 2002; 28 (Suppl.):7-11.
7. Wollina U, Dummer R, Brockmeyer NH et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003; 98:993-1001.
8. Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90:354-71.
9. Balmer C, Valley AW. Basic principles of cancer treatment and cancer chemotherapy. In: Pharmacotherapy: a Pathophysiologic Approach (Di Piro JT, Talbert RL, Hayes PE et al., eds), 2nd edn. Norwalk, CT: Appleton & Lange, 1993; 1879-929.
10. Coukell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Drugs 1997; 53:520-38.
11. Wollina U, Graefe T, Karte K. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 2001; 44:149-50.
12. Quaglino P, Fierro MT, Rossotto GL et al. Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy. Br J Dermatol 2004; 150:327-36.